Skip to main content
. 2019 Jul 23;10(45):4640–4654. doi: 10.18632/oncotarget.27061

Figure 1. Parallel expression of BHLHE40 and BHLHE41.

Figure 1

Sixty-one primary EC specimens were used to analyze the mRNA levels of BHLHE40 (A) and BHLHE41 (B). BHLHE40/41 mRNA levels in the EC group at an early stage (stage IA) were compared with those with advanced stages (at or more than stage IB). (C) The relationship between BHLHE40 and BHLHE41 mRNA levels from the 61 specimens was analyzed using Pearson’s product-moment correlation coefficient. r-values show correlation coefficients. The 61 EC samples were also analyzed for BHLHE40/41 expression levels by immunohistochemistry. Representative results are shown. A grade 1 endometrioid carcinoma (EAC) case at stage IA (D, E), another grade 2 EAC case at stage IA (F, G), a grade 3 EAC case at stage IB (H, I), and a serous carcinoma case at stage IVB (J, K). Immunohistochemical images with an anti-BHLHE40 antibody (D, F, H, J), and an anti-BHLHE41 antibody (E, G, I, K) are shown. The scale bars indicate 100 µm. The staining scores of immunohistochemical images were analyzed (L, M). The 61 cases were divided into an early stage group and an advanced stage group, as described above. (N) The relationship between BHLHE40 and BHLHE41 staining levels from the 61 specimens was analyzed using Pearson’s product-moment correlation coefficient.